Can Vancevir/Valganciclovir be reimbursed by medical insurance?

Valganciclovir The tablet form of the original drug was approved for sale by the National Medical Products Administration in 2019. However, due to factors such as a short time on the market, the drug has not yet entered the relevant regulations of the National Medical Insurance Administration, so it has not yet been able to enjoy medical insurance reimbursement.

Valganciclovir is mainly used to prevent diseases caused by cytomegalovirus (CMV) in people who have received organ transplants. CMV disease can cause serious infections in the body, including an eye infection called CMV retinitis, which can lead to blindness. Valganciclovir works by slowing the growth of the CMV virus. It helps prevent the infection from spreading to other parts of the body.

Valganciclovir is also used to treat cytomegalovirus retinitis in patients with advanced AIDS. This medication helps control cytomegalovirus retinitis and reduces the risk of blindness. Valganciclovir does not cure CMV disease. Some people may develop worsening CMV retinitis even with treatment. It is important to have regular eye exams with your doctor.

For domestic patients in need, they can only purchase valganciclovir for treatment at their own expense. This means that patients need to bear the cost of the drugs themselves and cannot rely on medical insurance for reimbursement. This may increase the financial burden for some patients with CMV-related disease. However, when choosing to purchase valganciclovir, patients still need to consider the effectiveness and safety of the drug and follow their doctor's recommendations and guidance. Although the drug is not covered by Medicare, it is still a recognized treatment option and plays an important role in certain circumstances.